trending Market Intelligence /marketintelligence/en/news-insights/trending/D4fFwiI4pVPiwPsJolUxJg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Immunomedics raises $272M from stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Immunomedics raises $272M from stock offering

Immunomedics Inc. closed a public offering of common shares, raising about $272 million in net proceeds.

The Morris Plains, N.J.-based company sold 16,428,572 shares for $17.50 each, including an extra 2,142,857 shares the offering's underwriters bought as part of their overallotment option.

Net proceeds will primarily be used to develop and commercialize the company's treatment for metastatic triple-negative breast cancer sacituzumab govitecan, which is under the U.S. Food and Drug Administration's review, Immunomedics said in a Dec. 9 press release.

Goldman Sachs & Co. LLC, BofA Securities, Cowen and Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering.